UK markets closed
  • NIKKEI 225

    26,170.30
    -841.03 (-3.11%)
     
  • HANG SENG

    23,807.00
    -482.90 (-1.99%)
     
  • CRUDE OIL

    86.34
    -1.01 (-1.16%)
     
  • GOLD FUTURES

    1,792.90
    -36.80 (-2.01%)
     
  • DOW

    34,107.12
    -60.97 (-0.18%)
     
  • BTC-GBP

    27,062.54
    -1,248.78 (-4.41%)
     
  • CMC Crypto 200

    824.65
    +5.14 (+0.63%)
     
  • ^IXIC

    13,373.89
    -168.23 (-1.24%)
     
  • ^FTAS

    4,230.83
    +38.13 (+0.91%)
     

Why Shares of Seres Therapeutics Are Up More Than 22% Wednesday

·2-min read
Why Shares of Seres Therapeutics Are Up More Than 22% Wednesday
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • MCRB
  • NSRGF

The company's revenue was $126.7 million, compared with only $1.4 million year over year, with most of the increase from collaboration revenue from Seres' co-commercialization license agreement with Nestlé Health Science. The improved financial numbers were only part of the story. On Wednesday, Seres said it had established a collaboration with Swiss pharmaceutical company Bacthera to manufacture SER-109, Seres' lead therapy to treat recurrent Clostridioides difficle infection (rCDI).

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting